Sep 22, 2023
Sandesh Seth, the CEO and Chairman of Actinium Pharmaceuticals uses targeted radiotherapy to effectively destroy diseased bone marrow and allow new bone marrow to take over the immune functions. This approach offers a way for those currently unable to receive a transplant to have a chance for a transplant and potentially be cured of acute myeloid leukemia.
Sandesh explains, "What we've shown in our Phase 3 program is we could take patients with acute myeloid leukemia, one of the deadliest cancers known to man, where drugs don't work on these patients, and they live about two to three months unless they can get a bone marrow transplant. With our lead drug, Iomab-B, we've shown that we can take non-transplantable patients because they're too weak or frail, and drugs don't work on them. And they have active disease, so they live only about three months. They can't get a transplant because they're too weak. And if you give them drugs, they may die. Or if you give them the conditioning needed to wipe out their diseased bone marrow, which is the factory from where the blood cancer spreads, they can't access the transplant."
"Iomab-B takes these non-transplant patients, it targets the disease, it kills the disease in a matter of days. It destroys the diseased bone marrow so that they can go and get a new bone marrow transplant or hemopoietic stem cells, which can then take over normal blood and immune function and restore the patient to health. It enables improved access and outcomes regarding the extension of survival and even cures in several patients, which we've shown in our Phase 3 trial. We will file licensing applications to the FDA later this year to get the drug hopefully approved next year and get it into the hands of patients."
#ActiniumPharma #Radiotherapies #Radiotherapy #BloodCancer #AML #BMT #Cancer #Oncology #Hematology #BioPharma #Pharmaceuticals #OneNews #FightCancer #CancerResearch
